> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Data Show Long-Term Shingrix Efficacy: GSK
- URL: https://www.fdaweb.com/data-show-long-term-shingrix-efficacy-gsk/
- Published: 2024-04-18T12:00:00.000Z
- Updated: 2026-09-14T14:28:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156801

GlaxoSmithKline says data from the ZOSTER-049 long-term follow-up Phase 3 trial of its Shingrix (recombinant zoster vaccine) demonstrated that it maintains efficacy against shingles for more than a decade in adults over age 50\. A company [statement](https://us.gsk.com/en-us/media/press-releases/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles/?ref=fdaweb.com) says the trial found 79.7% efficacy in participants aged 50 and over, six to 11 years after vaccination. No new safety concerns were identified in the follow-up period, the company says.